Containment Engineer In-Vitro Vaccination 
The Pharma Data
AUGUST 15, 2021
Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.
The Pharma Data
JANUARY 11, 2021
Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 16, 2023
In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering.
Pfizer
JANUARY 27, 2023
In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. In addition, to meet U.S.
Drug Discovery World
FEBRUARY 1, 2024
From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. For over a year, Evusheld provided prophylactic protection for immunocompromised people, a group that was often unable to benefit from vaccines.
The Pharma Data
DECEMBER 29, 2020
The academic partners of the consortium have been awarded €350,000 from Health Holland under the Eureka Program to develop a SARS-CoV-2-specific therapeutic nanomedicine that is administered via nasal inhalation and that can also be used for in vitro diagnostics. About Radboudumc.
The Pharma Data
JANUARY 24, 2021
Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. Read on to see. COVID-19-Related.
Expert insights. Personalized for you.
52 
Let's personalize your content